Condition: Advanced Cholangiocarcinoma · FGFR2 Fusions · Gene Rearrangement · Sponsor: Taiho Oncology, Inc.
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
This description comes directly from the study's public registry record.
Taiho Oncology, INC · +1 844-878-2446 · medicalinformation@taihooncology.com
Always discuss trial participation with your own doctor first.
| University of California San Diego UCSD - Moores Cancer Center | La Jolla, California, United States | Completed |
| Tampa General Hospital Cancer Institute | Tampa, Florida, United States | Withdrawn |
| Henry Ford Health System | Detroit, Michigan, United States | Completed |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Withdrawn |
| Texas Oncology | Abilene, Texas, United States | Completed |
| The Liver Institute at Methodist Dallas Medical Center | Dallas, Texas, United States | Completed |
| Texas Oncology Methodist DFW | Dallas, Texas, United States | Completed |
| Texas Onc Methodist (Charlton) | Dallas, Texas, United States | Completed |
| Texas Oncology - Northeast | Denton, Texas, United States | Completed |
| Center for Oncology and Blood Disorders | Houston, Texas, United States | Withdrawn |
| Hospital Britanico | Buenos Aires, Argentina | Completed |
| CEMIC | CABA, Argentina | Completed |
+ 53 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05727176